-
公开(公告)号：US07563441B2
公开(公告)日：2009-07-21
申请号：US11102403
申请日：2005-04-08
申请人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
发明人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2854 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S435/81
摘要： This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
摘要翻译： 本发明涉及抗P-选择素抗体，特别涉及含有源自人源的Fc部分并且不结合补体因子C1q的抗P-选择素抗体及其变体。 这些抗体具有新的和本发明的性质，为患有严重肢体缺血或外周动脉闭塞性疾病（CLI / PAOD）的患者带来益处。
-
2.发明授权Methods of inhibiting the binding of P-selectin to PSGL-1 with anti-P-selectin antibodies 有权用抗P-选择蛋白抗体抑制P-选择素与PSGL-1结合的方法公开(公告)号：US07824684B2
公开(公告)日：2010-11-02
申请号：US12768150
申请日：2010-04-27
申请人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
发明人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2854 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S435/81
摘要： This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
摘要翻译： 本发明涉及抗P-选择素抗体，特别涉及含有源自人源的Fc部分并且不结合补体因子C1q的抗P-选择素抗体及其变体。 这些抗体具有新的和本发明的性质，为患有严重肢体缺血或外周动脉闭塞性疾病（CLI / PAOD）的患者带来益处。
-
3.发明申请COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT 审中-公开具有抗BCL-2活性剂的II型抗CD20抗体的组合治疗公开(公告)号：US20090098118A1
公开(公告)日：2009-04-16
申请号：US12234739
申请日：2008-09-22
申请人： Thomas Friess , Christian Klein , Pamela Strein , Pablo Umana
发明人： Thomas Friess , Christian Klein , Pamela Strein , Pablo Umana
IPC分类号： A61K39/395 , A61P35/04
CPC分类号： A61K39/39558 , A61K31/495 , A61K39/39533 , A61K45/06 , A61K2039/505 , C07K16/2887 , A61K2300/00
摘要： The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and an anti-Bcl-2 active agent for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer.An aspect of the invention is a composition comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent.Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent.Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment) a type II anti-CD20 antibody and an anti-Bcl-2 active agent.
摘要翻译： 本发明涉及涉及用于治疗患有癌症的患者，特别是CD20表达癌症的患者的II型抗CD20抗体和抗Bcl-2活性剂的组合疗法。 本发明的一个方面是包含II型抗CD20抗体和抗Bcl-2活性剂的组合物。 本发明的另一方面是包含II型抗CD20抗体和抗Bcl-2活性剂的试剂盒。 本发明的另一方面是治疗患有癌症的患者的方法，包括向需要这种治疗的患者共同施用）II型抗CD20抗体和抗Bcl-2活性剂。
-
公开(公告)号：USRE43568E1
公开(公告)日：2012-08-07
申请号：US13187586
申请日：2011-07-21
申请人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan Van de Winkel , Martine Van Vugt
发明人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan Van de Winkel , Martine Van Vugt
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2854 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S435/81
摘要： This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
摘要翻译： 本发明涉及抗P-选择素抗体，特别涉及含有源自人源的Fc部分并且不结合补体因子C1q的抗P-选择素抗体及其变体。 这些抗体具有新的和本发明的性质，为患有严重肢体缺血或外周动脉闭塞性疾病（CLI / PAOD）的患者带来益处。
-
公开(公告)号：US07754867B2
公开(公告)日：2010-07-13
申请号：US12481623
申请日：2009-06-10
申请人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
发明人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
CPC分类号： C07K16/2854 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S435/81
摘要： This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
摘要翻译： 本发明涉及抗P-选择素抗体，特别涉及含有源自人源的Fc部分并且不结合补体因子C1q的抗P-选择素抗体及其变体。 这些抗体具有新的和本发明的性质，为患有严重肢体缺血或外周动脉闭塞性疾病（CLI / PAOD）的患者带来益处。
-
公开(公告)号：US20100209423A1
公开(公告)日：2010-08-19
申请号：US12768150
申请日：2010-04-27
申请人： YVO GRAUS , JACQUES HIMBER , MIRANDA JANSEN-MOLENAAR , DOROTHEE KLING , ERHARD KOPETZKI , PAUL PARREN , FRANK REBERS , BEAT STEINER , ANNE STERN , PAMELA STREIN , KAY-GUNNAR STUBENRAUCH , JAN VAN DE WINKEL , MARTINE VAN VUGT
发明人： YVO GRAUS , JACQUES HIMBER , MIRANDA JANSEN-MOLENAAR , DOROTHEE KLING , ERHARD KOPETZKI , PAUL PARREN , FRANK REBERS , BEAT STEINER , ANNE STERN , PAMELA STREIN , KAY-GUNNAR STUBENRAUCH , JAN VAN DE WINKEL , MARTINE VAN VUGT
IPC分类号： A61K39/395 , A61P29/00
CPC分类号： C07K16/2854 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S435/81
摘要： This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
摘要翻译： 本发明涉及抗P-选择素抗体，特别涉及含有源自人源的Fc部分并且不结合补体因子C1q的抗P-选择素抗体及其变体。 这些抗体具有新的和本发明的性质，为患有严重肢体缺血或外周动脉闭塞性疾病（CLI / PAOD）的患者带来益处。
-
公开(公告)号：US20050226876A1
公开(公告)日：2005-10-13
申请号：US11102403
申请日：2005-04-08
申请人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
发明人： Yvo Graus , Jacques Himber , Miranda Jansen-Molenaar , Dorothee Kling , Erhard Kopetzki , Paul Parren , Frank Rebers , Beat Steiner , Anne Stern , Pamela Strein , Kay-Gunnar Stubenrauch , Jan van de Winkel , Martine van Vugt
CPC分类号： C07K16/2854 , C07K2317/21 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , Y10S435/81
摘要： This invention relates to anti-P-selectin antibodies and, in particular, to anti-P-selectin antibodies and variants thereof that contain an Fc part derived from human origin and do not bind complement factor C1q. These antibodies have new and inventive properties causing a benefit for a patient suffering from critical limb ischemia or peripheral arterial occlusive disease (CLI/PAOD).
摘要翻译： 本发明涉及抗P-选择素抗体，特别涉及含有源自人源的Fc部分并且不结合补体因子C1q的抗P-选择素抗体及其变体。 这些抗体具有新的和本发明的性质，为患有严重肢体缺血或外周动脉闭塞性疾病（CLI / PAOD）的患者带来益处。
-
8.发明申请COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT 审中-公开具有抗BCL-2活性剂的II型抗CD20抗体的组合治疗公开(公告)号：US20120276085A1
公开(公告)日：2012-11-01
申请号：US13424506
申请日：2012-03-20
申请人： Thomas Friess , Christian Klein , Pamela Strein , Pablo Umana
发明人： Thomas Friess , Christian Klein , Pamela Strein , Pablo Umana
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： A61K39/39558 , A61K31/495 , A61K39/39533 , A61K45/06 , A61K2039/505 , C07K16/2887 , A61K2300/00
摘要： The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and an anti-Bcl-2 active agent for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and an anti-Bcl-2 active agent.
摘要翻译： 本发明涉及涉及用于治疗患有癌症的患者，特别是CD20表达癌症的患者的II型抗CD20抗体和抗Bcl-2活性剂的组合疗法。 本发明的一个方面是包含II型抗CD20抗体和抗Bcl-2活性剂的组合物。 本发明的另一方面是包含II型抗CD20抗体和抗Bcl-2活性剂的试剂盒。 本发明的另一方面是用于治疗患有癌症的患者的方法，包括向需要这种治疗的患者共同施用II型抗CD20抗体和抗Bcl-2活性剂。
-
9.发明申请COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT 审中-公开具有抗BCL-2活性剂的II型抗CD20抗体的组合治疗公开(公告)号：US20110287006A1
公开(公告)日：2011-11-24
申请号：US13190752
申请日：2011-07-26
申请人： Thomas Friess , Christian Klein , Pamela Strein , Pablo Umana
发明人： Thomas Friess , Christian Klein , Pamela Strein , Pablo Umana
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： A61K39/39558 , A61K31/495 , A61K39/39533 , A61K45/06 , A61K2039/505 , C07K16/2887 , A61K2300/00
摘要： The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and an anti-Bcl-2 active agent for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent. Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and an anti-Bcl-2 active agent.
摘要翻译： 本发明涉及涉及用于治疗患有癌症的患者，特别是CD20表达癌症的患者的II型抗CD20抗体和抗Bcl-2活性剂的组合疗法。 本发明的一个方面是包含II型抗CD20抗体和抗Bcl-2活性剂的组合物。 本发明的另一方面是包含II型抗CD20抗体和抗Bcl-2活性剂的试剂盒。 本发明的另一方面是用于治疗患有癌症的患者的方法，包括向需要这种治疗的患者共同施用II型抗CD20抗体和抗Bcl-2活性剂。
-
10.发明申请Combination Therapy of a Type II Anti-CD20 Antibody with an Anti-BCL-2 Active Agent 审中-公开II型抗CD20抗体与抗BCL-2活性剂的联合治疗公开(公告)号：US20110086025A1
公开(公告)日：2011-04-14
申请号：US12780640
申请日：2010-05-14
申请人： Thomas Friess , Christian Klein , Pamela Strein , Pablo Umana
发明人： Thomas Friess , Christian Klein , Pamela Strein , Pablo Umana
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： A61K39/39558 , A61K31/495 , A61K39/39533 , A61K45/06 , A61K2039/505 , C07K16/2887 , A61K2300/00
摘要： The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and an anti-Bcl-2 active agent for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer.An aspect of the invention is a composition comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent.Another aspect of the invention is a kit comprising a type II anti-CD20 antibody and an anti-Bcl-2 active agent.Yet another aspect of the invention is a method for the treatment of a patient suffering from cancer comprising co-administering, to a patient in need of such treatment, a type II anti-CD20 antibody and an anti-Bcl-2 active agent.
摘要翻译： 本发明涉及涉及用于治疗患有癌症的患者，特别是CD20表达癌症的患者的II型抗CD20抗体和抗Bcl-2活性剂的组合疗法。 本发明的一个方面是包含II型抗CD20抗体和抗Bcl-2活性剂的组合物。 本发明的另一方面是包含II型抗CD20抗体和抗Bcl-2活性剂的试剂盒。 本发明的另一方面是用于治疗患有癌症的患者的方法，包括向需要这种治疗的患者共同施用II型抗CD20抗体和抗Bcl-2活性剂。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.017 秒)
